{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:29:55Z","timestamp":1792448995420,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD081123"],"award-info":[{"award-number":["R01 HD081123"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00330-019-06569-y","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T19:03:20Z","timestamp":1576523000000},"page":"1790-1803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents"],"prefix":"10.1007","volume":"30","author":[{"given":"Florian","family":"Siedek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Muehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok J.","family":"Theruvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Avedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Pribnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri L.","family":"Spunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-819X","authenticated-orcid":false,"given":"Heike E.","family":"Daldrup-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"6569_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","volume":"33","author":"J Lohrke","year":"2016","unstructured":"Lohrke J, Frenzel T, Endrikat J et al (2016) 25 years of contrast-enhanced MRI: developments, current challenges and future perspectives. Adv Ther 33:1\u201328","journal-title":"Adv Ther"},{"key":"6569_CR2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","volume":"356","author":"SE Cowper","year":"2000","unstructured":"Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000\u20131001","journal-title":"Lancet"},{"key":"6569_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","volume":"21","author":"T Grobner","year":"2006","unstructured":"Grobner T (2006) Gadolinium\u2014a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104\u20131108","journal-title":"Nephrol Dial Transplant"},{"key":"6569_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1148\/radiol.13131669","volume":"270","author":"T Kanda","year":"2004","unstructured":"Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2004) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834\u2013841","journal-title":"Radiology"},{"key":"6569_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1148\/radiol.2018172746","volume":"288","author":"P Robert","year":"2018","unstructured":"Robert P, Fingerhut S, Factor C et al (2018) One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model. Radiology 288:424\u2013433","journal-title":"Radiology"},{"key":"6569_CR6","doi-asserted-by":"crossref","unstructured":"Frenzel T, Apte C, Jost G, Sch\u00f6ckel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 52:396\u2013404","DOI":"10.1097\/RLI.0000000000000352"},{"key":"6569_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/RLI.0000000000000241","volume":"51","author":"P Robert","year":"2016","unstructured":"Robert P, Violas X, Grand S et al (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 51:73\u201382","journal-title":"Invest Radiol"},{"key":"6569_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1148\/radiol.2015150337","volume":"275","author":"A Radbruch","year":"2015","unstructured":"Radbruch A, Weberling LD, Kieslich PJ et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783\u2013791","journal-title":"Radiology"},{"key":"6569_CR9","unstructured":"FDA Drug Safety Communication (2017) FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. U.S. Food and Drug Administration, Silver Spring, MD, USA. Available via https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm589213.htm. Accessed 14 Mar 2019"},{"key":"6569_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21656","volume":"85","author":"M Lu","year":"2010","unstructured":"Lu M, Cohen MH, Rieves D, Pazdur R (2010) FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85:315\u2013319","journal-title":"Am J Hematol"},{"key":"6569_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","volume":"39","author":"VS Balakrishnan","year":"2009","unstructured":"Balakrishnan VS, Rao M, Kausz AT et al (2009) Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 39:489\u2013496","journal-title":"Eur J Clin Invest"},{"key":"6569_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1592\/phco.30.1.70","volume":"30","author":"MH Schwenk","year":"2010","unstructured":"Schwenk MH (2010) Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 30:70\u201379","journal-title":"Pharmacotherapy"},{"key":"6569_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.rli.0000191367.61306.83","volume":"41","author":"GH Simon","year":"2006","unstructured":"Simon GH, Von Vopelius-Feldt J, Fu Y et al (2006) Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol 41:45\u201351","journal-title":"Invest Radiol"},{"key":"6569_CR14","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2217\/nnm.12.198","volume":"8","author":"A Khurana","year":"2013","unstructured":"Khurana A, Nejadnik H, Chapelin F et al (2013) Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. Nanomedicine (Lond) 8:1969\u20131983","journal-title":"Nanomedicine (Lond)"},{"key":"6569_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1148\/radiol.12112393","volume":"264","author":"A Khurana","year":"2012","unstructured":"Khurana A, Nejadnik H, Gawande R et al (2012) Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants. Radiology 264:803\u2013811","journal-title":"Radiology"},{"key":"6569_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1227\/01.NEU.0000255350.71700.37","volume":"60","author":"EA Neuwelt","year":"2007","unstructured":"Neuwelt EA, V\u00e1rallyay CG, Manninger S et al (2007) The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 60:601\u2013611","journal-title":"Neurosurgery"},{"key":"6569_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1345\/aph.1Q431","volume":"45","author":"KL Stabi","year":"2011","unstructured":"Stabi KL, Bendz LM (2011) Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Ann Pharmacother 45:1571\u20131575","journal-title":"Ann Pharmacother"},{"key":"6569_CR18","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.1021\/acsnano.8b03368","volume":"12","author":"L Henderson","year":"2018","unstructured":"Henderson L, Neumann O, Kaffes C et al (2018) Routes to potentially safer T1 magnetic resonance imaging contrast in a compact plasmonic nanoparticle with enhanced fluorescence. ACS Nano 12:8214\u20138223","journal-title":"ACS Nano"},{"key":"6569_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jmri.20235","volume":"21","author":"W Li","year":"2005","unstructured":"Li W, Tutton S, Vu AT et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21:46\u201352","journal-title":"J Magn Reson Imaging"},{"key":"6569_CR20","first-page":"231","volume":"11","author":"MR Prince","year":"2003","unstructured":"Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231\u2013240","journal-title":"J Xray Sci Technol"},{"key":"6569_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/jcbfm.2013.36","volume":"33","author":"CG Varallyay","year":"2013","unstructured":"Varallyay CG, Nesbit E, Fu R et al (2013) High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab 33:780\u2013786","journal-title":"J Cereb Blood Flow Metab"},{"key":"6569_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(14)70021-X","volume":"15","author":"C Klenk","year":"2014","unstructured":"Klenk C, Gawande R, Uslu L et al (2014) Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET\/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol 15:275\u2013285","journal-title":"Lancet Oncol"},{"key":"6569_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000087212","volume":"25","author":"R Landry","year":"2005","unstructured":"Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK (2005) Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 25:400\u2013410","journal-title":"Am J Nephrol"},{"key":"6569_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/RLI.0b013e31826dc151","volume":"47","author":"P Storey","year":"2012","unstructured":"Storey P, Lim RP, Chandarana H et al (2012) MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol 47:717\u2013724","journal-title":"Invest Radiol"},{"key":"6569_CR25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.ajkd.2008.08.001","volume":"52","author":"A Singh","year":"2008","unstructured":"Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L (2008) Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 52:907\u2013915","journal-title":"Am J Kidney Dis"},{"key":"6569_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1681\/ASN.2007101156","volume":"19","author":"BS Spinowitz","year":"2008","unstructured":"Spinowitz BS, Kausz AT, Baptista J et al (2008) Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19:1599\u20131605","journal-title":"J Am Soc Nephrol"},{"key":"6569_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/j.1523-1755.2005.00598.x","volume":"68","author":"BS Spinowitz","year":"2005","unstructured":"Spinowitz BS, Schwenk MH, Jacobs PM et al (2005) The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 68:1801\u20131807","journal-title":"Kidney Int"},{"key":"6569_CR28","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1158\/1078-0432.CCR-10-3420","volume":"17","author":"HE Daldrup-Link","year":"2011","unstructured":"Daldrup-Link HE, Golovko D, Ruffell B et al (2011) MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17:5695\u20135704","journal-title":"Clin Cancer Res"},{"key":"6569_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/radiol.13130858","volume":"269","author":"A Khurana","year":"2013","unstructured":"Khurana A, Chapelin F, Beck G et al (2013) Iron administration before stem cell harvest enables MR imaging tracking after transplantation. Radiology 269:186\u2013197","journal-title":"Radiology"},{"key":"6569_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.suc.2016.05.012","volume":"96","author":"RF Williams","year":"2016","unstructured":"Williams RF, Fernandez-Pineda I, Gosain A (2016) Pediatric sarcomas. Surg Clin North Am 96:1107\u20131125","journal-title":"Surg Clin North Am"},{"key":"6569_CR31","unstructured":"FDA Drug Safety Communication (2015) FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol) U.S. Food and Drug Administration, Silver Spring, MD, USA. Available via http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm440138.htm. Accessed 16 Mar 2019"},{"key":"6569_CR32","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","volume":"43","author":"T Frenzel","year":"2008","unstructured":"Frenzel T, Lengsfeld P, Schirmer H, H\u00fctter J, Weinmann HJ (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 \u00b0C. Invest Radiol 43:817\u2013828","journal-title":"Invest Radiol"},{"key":"6569_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00004424-200001000-00004","volume":"35","author":"B Tombach","year":"2000","unstructured":"Tombach B, Bremer C, Reimer P et al (2000) Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 35:35\u201340","journal-title":"Invest Radiol"},{"key":"6569_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/01.rli.0000184756.66360.d3","volume":"40","author":"M Rohrer","year":"2005","unstructured":"Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715\u2013724","journal-title":"Invest Radiol"},{"key":"6569_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/RLI.0000000000000434","volume":"53","author":"G Knobloch","year":"2018","unstructured":"Knobloch G, Colgan T, Wiens CN et al (2018) Relaxivity of ferumoxytol at 1.5 T and 3.0 T. Invest Radiol 53:257\u2013263","journal-title":"Invest Radiol"},{"key":"6569_CR36","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jmri.21969","volume":"30","author":"S Aime","year":"2009","unstructured":"Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30:1259\u20131267","journal-title":"J Magn Reson Imaging"},{"key":"6569_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1148\/radiol.2017162759","volume":"284","author":"HE Daldrup-Link","year":"2017","unstructured":"Daldrup-Link HE (2017) Ten things you might not know about iron oxide nanoparticles. Radiology 284:616\u2013629","journal-title":"Radiology"},{"key":"6569_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1148\/radiol.2016151066","volume":"281","author":"S Power","year":"2016","unstructured":"Power S, Talbot N, Kucharczyk W, Mandell DM (2016) Allergic-like reactions to the MR imaging contrast agent gadobutrol: a prospective study of 32 991 consecutive injections. Radiology 281:72\u201377","journal-title":"Radiology"},{"key":"6569_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.eclinm.2018.07.002","volume":"1","author":"O Clement","year":"2018","unstructured":"Clement O, Dewachter P, Mouton-Faivre C et al (2018) Immediate hypersensitivity to contrast agents: the French 5-year CIRTACI Study. EClinicalMedicine 1:51\u201361","journal-title":"EClinicalMedicine"},{"key":"6569_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.kint.2016.12.037","volume":"92","author":"GB Toth","year":"2017","unstructured":"Toth GB, Varallyay CG, Horvath A et al (2017) Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 92:47\u201366","journal-title":"Kidney Int"},{"key":"6569_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jmri.20969","volume":"26","author":"O Dietrich","year":"2007","unstructured":"Dietrich O, Raya JG, Reeder SB, Reiser MF, Schoenberg SO (2007) Measurement of signal-to-noise ratios in MR images: influence of multichannel coils, parallel imaging, and reconstruction filters. J Magn Reson Imaging 26:375\u2013385","journal-title":"J Magn Reson Imaging"},{"key":"6569_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.mri.2012.05.005","volume":"30","author":"X Li","year":"2012","unstructured":"Li X, Huang W, Rooney WD (2012) Signal-to-noise ratio, contrast-to-noise ratio and pharmacokinetic modeling considerations in dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 30:1313\u20131322","journal-title":"Magn Reson Imaging"},{"key":"6569_CR43","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1148\/radiol.12111472","volume":"266","author":"S Gahramanov","year":"2013","unstructured":"Gahramanov S, Muldoon LL, Varallyay CG et al (2013) Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 266:842\u2013852","journal-title":"Radiology"},{"key":"6569_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/neuonc\/noq172","volume":"13","author":"E D\u00f3sa","year":"2011","unstructured":"D\u00f3sa E, Guillaume DJ, Haluska M et al (2011) Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol 13:251\u2013260","journal-title":"Neuro Oncol"},{"key":"6569_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11060-016-2175-0","volume":"129","author":"BE Hamilton","year":"2016","unstructured":"Hamilton BE, Woltjer RL, Prola-Netto J et al (2016) Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. J Neurooncol 129:301\u2013309","journal-title":"J Neurooncol"},{"key":"6569_CR46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/00004424-199611000-00004","volume":"31","author":"TJ Vogl","year":"1996","unstructured":"Vogl TJ, Hammerstingl R, Schwarz W et al (1996) Magnetic resonance imaging of focal liver lesions: comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol 31:696\u2013708","journal-title":"Invest Radiol"},{"key":"6569_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00261-002-0064-9","volume":"28","author":"K Takahama","year":"2003","unstructured":"Takahama K, Amano Y, Hayashi H, Ishihara M, Kumazaki T (2003) Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging. Abdom Imaging 28:525\u2013530","journal-title":"Abdom Imaging"},{"key":"6569_CR48","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1148\/radiol.2253011854","volume":"225","author":"C del Frate","year":"2002","unstructured":"del Frate C, Bazzocchi M, Mortele KJ et al (2002) Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 225:776\u2013772","journal-title":"Radiology"},{"key":"6569_CR49","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ejrad.2009.09.002","volume":"77","author":"K Hekimoglu","year":"2011","unstructured":"Hekimoglu K, Ustundag Y, Dusak A et al (2011) Small colorectal liver metastases: detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging. Eur J Radiol 77:468\u2013472","journal-title":"Eur J Radiol"},{"key":"6569_CR50","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-18-0673","volume":"24","author":"M Aghighi","year":"2018","unstructured":"Aghighi M, Theruvath AJ, Pareek A et al (2018) Magnetic resonance imaging of tumor-associated macrophages: clinical translation. Clin Cancer Res 24:4110\u20134118","journal-title":"Clin Cancer Res"},{"key":"6569_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2106\/JBJS.16.01461","volume":"100","author":"C Th\u00e9venin-Lemoine","year":"2018","unstructured":"Th\u00e9venin-Lemoine C, Destombes L, Vial J et al (2018) Planning for bone excision in Ewing sarcoma: post-chemotherapy MRI more accurate than pre-chemotherapy MRI assessment. J Bone Joint Surg Am 100:13\u201320","journal-title":"J Bone Joint Surg Am"},{"key":"6569_CR52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF02012438","volume":"23","author":"M Panuel","year":"1993","unstructured":"Panuel M, Gentet JC, Scheiner C et al (1993) Physeal and epiphyseal extent of primary malignant bone tumors in childhood\u2014correlation of preoperative MRI and the pathologic examination. Pediatr Radiol 23:421\u2013424","journal-title":"Pediatr Radiol"},{"key":"6569_CR53","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/jmri.24320","volume":"39","author":"P Storey","year":"2014","unstructured":"Storey P, Arbini AA (2014) Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects. J Magn Reson Imaging 39:1401\u20131410","journal-title":"J Magn Reson Imaging"},{"key":"6569_CR54","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00330-001-1270-5","volume":"12","author":"HE Daldrup-Link","year":"2002","unstructured":"Daldrup-Link HE, Rummeny EJ, Ihssen B, Kienast J, Link TM (2002) Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin\u2019s lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. Eur Radiol 12:1557\u20131566","journal-title":"Eur Radiol"},{"key":"6569_CR55","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1148\/radiology.175.2.2326474","volume":"175","author":"R Weissleder","year":"1990","unstructured":"Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175:489\u2013493","journal-title":"Radiology"},{"key":"6569_CR56","doi-asserted-by":"publisher","first-page":"e0142665","DOI":"10.1371\/journal.pone.0142665","volume":"10","author":"M Aghighi","year":"2015","unstructured":"Aghighi M, Golovko D, Ansari C et al (2015) Imaging tumor necrosis with ferumoxytol. PLoS One 10:e0142665","journal-title":"PLoS One"},{"key":"6569_CR57","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1148\/radiol.2019181659","volume":"291","author":"A Cromb\u00e9","year":"2019","unstructured":"Cromb\u00e9 A, Marcellin P-J, Buy X et al (2019) Soft-tissue sarcomas: assessment of MRI features correlating with histologic grade and patient outcome. Radiology 291:710\u2013721","journal-title":"Radiology"},{"key":"6569_CR58","doi-asserted-by":"crossref","unstructured":"Salunke AA, Shah J, Gupta N, Pandit J (2016) Pathologic fracture in osteosarcoma: association with poorer overall survival. Eur J Surg Oncol 42:889\u2013890","DOI":"10.1016\/j.ejso.2016.02.255"},{"key":"6569_CR59","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s00247-016-3605-z","volume":"46","author":"A Luhar","year":"2016","unstructured":"Luhar A, Khan S, Finn JP et al (2016) Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol 46:1332\u20131340","journal-title":"Pediatr Radiol"},{"key":"6569_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejrad.2018.05.021","volume":"105","author":"S Yedururi","year":"2018","unstructured":"Yedururi S, Chawla S, Amini B et al (2018) Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. Eur J Radiol 105:49\u201355","journal-title":"Eur J Radiol"},{"key":"6569_CR61","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/jmri.22568","volume":"33","author":"CU Lee","year":"2011","unstructured":"Lee CU, Glockner JF (2011) Vascular staging of renal and adrenal malignancies with a noncontrast enhanced steady state free precession technique. J Magn Reson Imaging 33:1406\u20131413","journal-title":"J Magn Reson Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-019-06569-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-019-06569-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-019-06569-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T18:34:16Z","timestamp":1722191656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-019-06569-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["6569"],"URL":"https:\/\/doi.org\/10.1007\/s00330-019-06569-y","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Dr. Heike E. Daldrup-Link, MD PhD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (Tie Liang EdD) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board due to the retrospective nature of this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Three of the 22 study subjects have previously been investigated by the following two studies: Muehe A et al (Mol Imaging Biol, 2018; 20:324\u2013335) and Aghighi M et al (Clin Cancer Res, 2018; 24:4110\u20134118). These previous studies focused on tumour detection with PET\/MRI (Mol Imaging Biol, 2018; 20:324\u2013335) or imaging of tumour-associated macrophages (Clin Cancer Res, 2018; 24:4110\u20134118). Our current study compares the performance of ferumoxytol- and gadolinium-enhanced scans. None of the previous studies compared Fe- and Gd-enhanced MRI scans.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 Retrospective\u2022 Diagnostic study\u2022 Performed at one institution","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}